UroGen Pharma to Present at Upcoming Investor Conferences
Cowen 43rd Annual
-
Panel Presentation Date:
Tuesday, March 7 th from12:50-1:50pm ET - Webcast Link: https://wsw.com/webcast/cowen132/panel12/2317014
Oppenheimer 33rd Annual Healthcare Conference —
-
Presentation Date:
Tuesday, March 14 th from10:40-11:10am ET - Webcast Link: https://wsw.com/webcast/oppenheimer27/urgn/2810892
Webcasts for both the Cowen and Oppenheimer presentations will be available via the Investors section of UroGen’s website, www.urogen.com. A replay of each webcast will be available on the Company’s website for approximately 30 days.
About
UroGen is biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel™ reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen’s first commercial product JELMYTO (mitomycin) for pyelocalyceal solution, and investigational treatment UGN-102 (mitomycin) for intravesical solution for patients with low-grade non-muscle invasive bladder cancer, are designed to ablate tumors by non-surgical means. UroGen is headquartered in
View source version on businesswire.com: https://www.businesswire.com/news/home/20230301005965/en/
INVESTOR CONTACT:
Senior Director, Investor Relations
vincent.perrone@urogen.com
609-460-3588 ext. 1093
MEDIA CONTACT:
cindy.romano@urogen.com
908-963-7827
Source:
